Longeveron to Announce Fourth Quarter and Full Year 2021 Financial Results, on March 11, 2022GlobeNewsWire • 03/07/22
Longeveron Adds Seasoned Biotech Executive Todd Girolamo to Its Board of DirectorsGlobeNewsWire • 02/17/22
Longeveron: Speculative Biotech Worth A Look On Rare Disease, Aging, And Alzheimer's FocusesSeeking Alpha • 02/15/22
Longeveron Announces Publication of Lomecel-B Phase 2b Trial Design in Journal of Frailty and AgingGlobeNewsWire • 01/12/22
Longeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer's DiseaseGlobeNewsWire • 01/05/22
Longeveron to Participate in the H.C. Wainwright BioConnect 2022 Virtual ConferenceGlobeNewsWire • 01/04/22
5 Short Squeeze Candidates To Watch: Petros Pharmaceuticals, iSpecimen Top The List AgainBenzinga • 12/20/21
5 Short Squeeze Candidates To Watch: Petros Pharma Tops List With 254% Cost To Borrow, One Of Highest Figures On RecordBenzinga • 12/13/21
Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS)GlobeNewsWire • 12/06/21